Monthly Prescribing Reference

New Tablet Formulation of Livmarli Gets FDA Approval

When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
PharmTech

Chewable Tablets: A Review of Formulation Considerations

This paper reviews considerations for the formulation of chewable tablets including sensory characteristics, chewability assessment, and drug release. Chewable tablets are a versatile dosage form ...
Yahoo Finance

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options SAN CARLOS, Calif., June 11, ...
Monthly Prescribing Reference

New Tablet Formulation of Calquence Approved for CLL, SLL, MCL

The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules. The Food and Drug ...
Seeking Alpha

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new ...
Business Wire

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA ®

BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
PMLiVE

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
PharmiWeb

CD Formulation Provides Pharmaceutical Testing on Tablet Fragility, Dissolution, and Disintegration

Pharmaceutical testing is a must to ensure that all medications meet the top quality, safety, and performance requirements before they enter the market. CD Formulation’s cGMP-compliant laboratory is ...
PharmTech

Development of Mini-Tablet and Multi-Unit Pellet Systems

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles. Multi-unit pellet systems (MUPS) and intelligently encapsulated mini-tablet systems (EMTS) have unique ...
Nasdaq

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

BASEL, Switzerland--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
PharmiWeb

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the ...